Marvel Biosciences Corp. MBCOF
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.04% | -25.17% | -58.07% | -31.35% | 25.94% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.91% | 144.25% | 154.81% | 168.14% | 1,083.84% |
| Change in Net Operating Assets | 72.91% | -139.01% | 585.33% | 52.94% | -84.66% |
| Cash from Operations | 32.50% | -45.70% | 13.83% | 4.94% | 12.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -40.33% | 253.54% | 240.90% | 104.28% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 71.44% | -180.25% | -180.25% | -180.25% | -- |
| Cash from Financing | -37.37% | 249.68% | 61.49% | -7.61% | 156.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.25% | 138.59% | 327.85% | -7.28% | 119.98% |